吗氯贝胺

吗氯贝胺
臨床資料
商品名（英语：Drug nomenclature）	Amira, Aurorix, Clobemix, Depnil, Manerix
AHFS/Drugs.com	Micromedex详细消费者药物信息
懷孕分級	澳: B3 ; ;
给药途径	oral
ATC碼	N06AG02 (WHO) ;
法律規範狀態
法律規範	澳：限医生处方（S4）; 加：处方药（℞-only）; 英：处方药（℞-only） (POM);
藥物動力學數據
生物利用度	55-95% (increases with repeat administration)
血漿蛋白結合率	50%
药物代谢	Hepatic
生物半衰期	1-2 hours, 4 hours (elderly)
排泄途徑	Renal, Faecal (<5%)
识别信息
	IUPAC命名法 4-chloro-N-(2-morpholin-4-ylethyl)benzamide; ;
CAS号	71320-77-9
PubChem CID	4235;
IUPHAR/BPS	7428;
DrugBank	DB01171 ;
ChemSpider	4087 ;
UNII	PJ0Y7AZB63;
KEGG	D02561 ;
ChEBI	CHEBI:83531 ;
ChEMBL	ChEMBL86304 ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID9040554 ;
ECHA InfoCard	100.163.935
化学信息
化学式	C13H17ClN2O2
摩尔质量	268.739 g/mol
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES Clc1ccc(cc1)C(=O)NCCN2CCOCC2;
	InChI InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17) ; Key:YHXISWVBGDMDLQ-UHFFFAOYSA-N ;

吗氯贝胺（商品名也作Amira、Aurorix、^[5]Clobemix、Depnil或Manerix）是主要用于治疗抑郁症和社交焦虑的单胺氧化酶A（RIMA）药物的可逆抑制剂。^[6]它在美国不被允许使用，但在其它西方国家，例如英国和澳大利亚（TGA于2000年12月）是被批准使用的。^[7]它由罗氏公司的附属公司生产。起初，Aurorix也在南非由罗氏公司供应，但在专利期满之后撤回，Cipla Medpro's Depnil和Pharma Dynamic's Clorix的成本减半。

当吗氯贝胺与胺类混用时，如含酪胺的食物或升压胺类药物，不会出现显著的血压升高，这与较老的非选择性和不可逆单胺氧化酶抑制剂（MAOI）不同，后者的混用会导致血压严重上升。由于不会造成抗胆碱剂、心血管、认知与精神运动损伤，吗氯贝胺在老年人以及心血管疾病患者中是有利的。^[6]

参考文献

^ Fitton, A; Faulds, D; Goa, KL. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs. April 1992, 43 (4): 561–596. PMID 1377119. doi:10.2165/00003495-199243040-00009.
^ ^2.0 ^2.1 Schoerlin, MP; Mayersohn, M; Korn, A; Eggers, H. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. Clinical Pharmacology and Therapeutics. October 1987, 42 (4): 395–404. PMID 3665338.
^ Freeman, H. Moclobemide. Lancet. December 1993, 342 (8886-8887): 1528–1532. PMID 7902906. doi:10.1016/S0140-6736(05)80090-X.
^ Gex-Fabry, M; Balant-Gorgia, AE; Balant, LP. Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. Therapeutic Drug Monitoring. February 1995, 17 (1): 39–46. PMID 7725375. doi:10.1097/00007691-199502000-00007.
^ Scheen AJ. [Drug of the month. Moclobemide (Aurorix)]. Rev Med Liege. May 1994, 49 (5): 291–2. PMID 8023056 （法语）.
^ ^6.0 ^6.1 Fulton B, Benfield P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. September 1996, 52 (3): 450–74. PMID 8875133. doi:10.2165/00003495-199652030-00013.
^ PRODUCT INFORMATION MOCLOBEMIDE SANDOZ® 150mg and 300mg TABLETS. TGA eBusiness Services. Sandoz. 6 March 2012 [16 October 2013]. （原始内容存档于2020-09-21）.

拓展阅读

Scientific Information on Aurorix (German)
PubChem Substance Summary: Moclobemide（页面存档备份，存于互联网档案馆） National Center for Biotechnology Information.

[1] Fitton, A; Faulds, D; Goa, KL. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs. April 1992, 43 (4): 561–596. PMID 1377119. doi:10.2165/00003495-199243040-00009.

[MAOA-2] 2.0 ^2.1 Schoerlin, MP; Mayersohn, M; Korn, A; Eggers, H. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. Clinical Pharmacology and Therapeutics. October 1987, 42 (4): 395–404. PMID 3665338.

[Lancet-3] Freeman, H. Moclobemide. Lancet. December 1993, 342 (8886-8887): 1528–1532. PMID 7902906. doi:10.1016/S0140-6736(05)80090-X.

[4] Gex-Fabry, M; Balant-Gorgia, AE; Balant, LP. Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. Therapeutic Drug Monitoring. February 1995, 17 (1): 39–46. PMID 7725375. doi:10.1097/00007691-199502000-00007.

[pmid8023056-5] Scheen AJ. [Drug of the month. Moclobemide (Aurorix)]. Rev Med Liege. May 1994, 49 (5): 291–2. PMID 8023056 （法语）.

[pmid8875133-6] 6.0 ^6.1 Fulton B, Benfield P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. September 1996, 52 (3): 450–74. PMID 8875133. doi:10.2165/00003495-199652030-00013.

[SANDOZ-7] PRODUCT INFORMATION MOCLOBEMIDE SANDOZ® 150mg and 300mg TABLETS. TGA eBusiness Services. Sandoz. 6 March 2012 [16 October 2013]. （原始内容存档于2020-09-21）.

[5]

[6]

[7]

[1]

[2]

[3]

[4]